Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Woman throwing punch at punching bag.

Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics

(As of June 30, 2024)

  • $167M

    TTM Revenue

  • $25-30M*

    Adj. EBITDA expected in 2024


    ~15%

    Adj. EBITDA
    Margin

  • $63M

    Cash balance

    with no debt

  • #1

    OA Pain
    U.S. Market Share


    ~25M

    Injections
    Worldwide

*Anticipate towards the lower end of range

Recent News
Oct 4, 2024

BEDFORD, Mass., October 4 , 2024 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 2024, Anika...

Sep 9, 2024

BEDFORD, Mass., September 9, 2024 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on September 3, 2024,...

Aug 15, 2024

BEDFORD, Mass., August 15, 2024 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on August 1, 2024, Anika...

All Press Releases

Featured Event
Thursday, August 15, 2024
11:30am EDT

See All Events

Current Investor Presentation
Investor Contacts

Primary IR Contact

  • Matt Hall

    Director, Corporate Development and Investor Relations

    Anika Therapeutics, Inc.

    Phone: (781) 457-9554

    Email: investorrelations@anika.com

  • Transfer Agent

    Equiniti Trust Company LLC

    6201 15th Avenue

    Brooklyn NY 11219

    Phone: (800) 937-5449

Want Alerts? Sign up for alerts and never miss an Investor update!

Subscribe

To Top